ACR-2316
Advanced Solid Tumors
Key Facts
About Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology company leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted therapies matched to patients via predictive OncoSignature tests. Its strategy centers on in-licensing and internally developing small molecule inhibitors, with a lead Phase 2 asset, ACR-368, and a dual-inhibitor clinical candidate, ACR-2316. The company aims to improve therapeutic outcomes by directly profiling the functional protein drivers of cancer, a paradigm shift from traditional genomics.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |